Join us for a live symposium on the *LipoSonix* system at the Anti-Aging Medicine World Congress (AMWC), April 8-10, 2010

Utilizing High Intensity Focused Ultrasound for Effective Fat Reduction: Proven Science and Clinical Results

Featuring dermatologic surgeon Afschin Fatemi, M.D. and Dermatologist, Jean-Michel Mazer, M.D., this symposium will highlight the performance and benefits of the innovative *LipoSonix* system for non-invasive body sculpting, including a simulated demonstration.

The *LipoSonix* system uses high intensity focused ultrasound (HIFU) to destroy anterior abdominal fat in the treatment area with one treatment. The focused energy penetrates deep into the subcutaneous adipose tissue causing cell necrosis. The result is a reduction of targeted subcutaneous fat in the treatment area with no damage to the surrounding and overlying tissues. This leading-edge process provides visible reduction 8 to 12 weeks after a single one-hour treatment, requires little or no patient downtime, and offers high patient satisfaction (average 2.8 cm waist circumference reduction—office visit time may vary). 91% of patients responding to a *LipoSonix* Post-treatment Exit Survey reported improvement in their abdominal flatness.[1]

For an insightful overview of the *LipoSonix* system, including simulated demonstration, attend the live symposium:

Thursday, April 8, 2010 • 16:30–17:30 p.m.

Monte-Carlo • Grimaldi Forum, Ravel 2 level +1

Be sure to visit us at AMWC, Booth D-10!

See reverse side for Important Safety Information.

The *LipoSonix* system uses non-invasive, focused ultrasound to treat subcutaneous abdominal adipose tissue.

Important Safety Information

During treatment as recommended, patients may experience discomfort, pain, cold, prickling, tingling, or warmth. The most common post-treatment side effects include temporary erythema, mild ecchymosis, discomfort, and edema.

The *LipoSonix* system is not for use in patients with a coagulation disorder, using anticoagulants or platelet inhibitors, or who have an implanted electrical device. Not for use in patients with a BMI >30 or in areas with less than 1 cm of adipose tissue beyond the selected focal depth, or in areas previously treated with injection lipolysis, liposuction, abdominoplasty or other surgery including laparoscopic, or where hernia, implanted material, sensory loss or dysesthesia are present. Treatment is contraindicated for patients with cancer, systemic disease, or who are pregnant or suspected to be pregnant.

For additional product and safety information please visit www.LipoSonix.com or refer to the *LipoSonix* System User Manual.

Reference:
1. Phase 2 Studies: P-0003, P-OUS, CDN-01. 2008. Sponsored by LipoSonix, Inc. Data on file, Medicis Technologies Corporation.

MEDICIS TECHNOLOGIES™